Airway Clearance Devices Medical Policy

Coverage Summary

Scope: This policy (Policy Number 2026T0052NN, Effective Date January 1, 2026) defines medical necessity and evidence-based coverage for airway clearance devices for UnitedHealthcare Commercial and Individual Exchange plans. It primarily addresses high-frequency chest wall oscillation (HFCWO) systems (vest-type HFCWC/HFCWO devices) for home use and specifies covered indications of neuromuscular disease (NMD), bronchiectasis, and cystic fibrosis (CF) with required documentation and trial requirements.

High-level device/indication overview: HFCWO (vest) systems — covered when clinical criteria and an initial two-month rental trial are met; Intrapulmonary Percussive Ventilation (IPV) devices for home use — considered unproven and not medically necessary; Combination CPEP/CHFO/OLE devices (oscillation + lung expansion + nebulization) — considered unproven and not medically necessary. The policy includes referenced HCPCS and ICD-10 code lists and evidence summaries to support coverage positions.

Key thresholds and quick stats

Peak Cough Flow threshold< 270 L/min

Maximal Expiratory Pressure threshold< 60 cm H2O

Required rental trial duration2 months

Covered indications count3

Policy effective date2026-01-01

Medical Necessity Criteria

High-Frequency Chest Wall Oscillation (HFCWO) Systems - Medical Necessity

Covered when ALL of the following are met:

ALL of the following

Diagnosis of one of the following: neuromuscular disease, bronchiectasis, or cystic fibrosis (see ICD-10 code list in Applicable Codes).
Refer to the ICD-10 code list in Applicable Codes for codes that support these diagnoses.
A documented two-month rental trial of a high-frequency chest wall oscillation (HFCWO) system demonstrating individual tolerance and efficacy.
The initial rental trial is required prior to determination of ongoing medical necessity.
Ongoing use
- For ongoing (post-trial) use, documentation must meet InterQual criteria for secretion clearance devices (Client Defined, CP: Durable Medical Equipment, Secretion Clearance Devices (Custom) - UHG).

Devices Considered Unproven / Not Medically Necessary

Combination CPEP/CHFO/OLE and Intrapulmonary Percussive Ventilation (IPV) Devices - Not Medically Necessary

Considered unproven and not medically necessary due to insufficient evidence:

ANY of the following

OLE devices: Combination continuous positive expiratory pressure (CPEP), continuous high frequency oscillation (CHFO), and nebulized medication therapy devices for oscillation and lung expansion (OLE)
Home IPV: Intrapulmonary percussive ventilation (IPV) devices for home use

Devices Considered Unproven / Not Medically Necessary

Due to insufficient quality evidence or consistency of findings, the following are considered unproven and not medically necessary:

ALL of the following

Coding (HCPCS / ICD-10 / FDA Classification)

DME / Device HCPCS Codes (referenced)HCPCS

E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device
E0481	Intrapulmonary percussive ventilation system and related accessories
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each
A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter)
A7025	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each
A7026	High frequency chest wall oscillation system hose, replacement for use with patient-owned equipment, each

Diagnosis Codes (ICD-10) referenced for covered indicationsICD-10

A80.0	Acute paralytic poliomyelitis, vaccine-associated
A80.1	Acute paralytic poliomyelitis, wild virus, imported
A80.2	Acute paralytic poliomyelitis, wild virus, indigenous
A80.30	Acute paralytic poliomyelitis, unspecified
A80.39	Other acute paralytic poliomyelitis
A80.4	Acute nonparalytic poliomyelitis
A80.9	Acute poliomyelitis, unspecified
B91	Sequelae of poliomyelitis
E74.02	Pompe disease
E74.4	Disorders of pyruvate metabolism and gluconeogenesis

1–10 of 61

1/7

FDA product classification referencedmixed

BYI	FDA product code for High-Frequency Chest Wall Compression Devices (informational)

Provider Actions & Operational Requirements

Prior Authorization

Initial two-month rental trial required

Providers must arrange an initial two-month rental trial for high-frequency chest wall oscillation (HFCWO) systems to confirm individual tolerance and effectiveness before ongoing coverage will be considered. Ongoing coverage for HFCWO after the rental trial requires that InterQual clinical criteria (Durable Medical Equipment, Secretion Clearance Devices) are met.

Affected codes: E0483, E0469, A7021, A7025, A7026

Denial Risk

Noncoverage for unproven devices/indications

Claims for combination OLE (continuous positive expiratory pressure/continuous high frequency oscillation/nebulized medication) devices and home intrapulmonary percussive ventilation (IPV) devices, as well as HFCWO when used for indications not supported by evidence, are considered unproven and not medically necessary. Such claims are at risk for denial.

Background and Evidence Summary

Background — pathophysiology and rationale: In healthy individuals, mucociliary clearance and coughing clear airway secretions; when secretions are excessive, viscous, or cough is ineffective (eg, in asthma, COPD, CF, mucociliary disorders, neuromuscular disease), secretions accumulate, obstruct airways, impair gas exchange, and increase infection risk. Airway obstruction can lead to bronchiectasis.

Device mechanisms and rationale: HFCWO (vest) systems are a mechanical form of chest physiotherapy that use an inflatable vest connected to an air-pulse generator that rapidly inflates and deflates (up to ~20 times per second) to produce external chest wall oscillation; the vibratory forces are thought to reduce mucus viscosity and assist mucociliary clearance. IPV delivers intrapulmonary percussive mini-bursts (more than ~200 per minute) of gas via a mouthpiece to mobilize endobronchial secretions and help resolve patchy atelectasis. HFCWO and IPV are intended to improve secretion mobilization and enable independent airway clearance when coughing is inadequate.

Rationale for coverage decisions: Because the evidence base varies by device and indication (reviews of randomized trials, systematic reviews, cohort/registry studies show mixed quality and results), the policy supports HFCWO for specified indications with a required two-month rental trial to confirm individual tolerance and efficacy, while recommending that IPV and combination OLE therapies remain unproven for routine home use pending higher-quality evidence.

Evidence / Source	Key finding
HFCWO rental trial requirement (policy)	Two-month home rental trial required and considered proven/medically necessary for NMD, bronchiectasis, and CF to confirm tolerance and efficacy before ongoing coverage
Systematic review — Huang et al. 2022 (AECOPD)	Meta-analysis (13 RCTs, 756 pts) found increased expectorated sputum and shorter hospital stay with HFCWO but no significant improvement in FEV1/oxygenation; heterogenous and low-certainty evidence
Cochrane / PEP vs HFCWO (McIlwaine 2019; Main & Rand 2023; Morrison & Milroy 2020)	Cochrane reviews report low–very low certainty overall; high‑quality evidence that PEP mask reduced pulmonary exacerbations versus HFCWO in CF long‑term studies; no clear superiority of oscillation devices overall
Registry / observational (Barto et al. 2020)	Large registry (n~2596) in non‑CF bronchiectasis showed reductions in hospitalizations and antibiotic use and improved self‑reported airway clearance after HFCWO initiation; non‑randomized evidence
ALS RCTs (Chaisson 2006; Lange et al. 2006)	Mixed RCT results: one small pilot (Chaisson) found no improvement in FVC decline or time to death; another small RCT (Lange) suggested slowed FVC decline and less breathlessness at 12 weeks; limited by small sample sizes
OLE evidence (Huynh et al. 2019)	Multicenter non‑randomized prospective study in high‑risk postop patients reported decreased postoperative pulmonary complications, ventilator time, and hospital LOS versus historical/control; authors call for RCTs
IPV evidence — systematic reviews and small RCTs (Hassan 2021; Reychler 2018; Nicolini 2018)	Evidence is weak/inconsistent: some small trials show symptom or physiologic improvements (exacerbation/gas exchange or dyspnea) but overall insufficient quality/consistency to recommend routine home use; minor adverse events reported

Definitions

Definitions:

Bronchiectasis — a chronic respiratory disease confirmed radiographically (high-resolution CT) characterized by airway dilation and clinical manifestations of recurrent, chronic, or refractory infections; clinically significant bronchiectasis includes at least two of: cough most days, sputum production most days, or a history of exacerbations.

HFCWO (High-Frequency Chest Wall Oscillation) — an external chest wall oscillation device (inflatable vest and air-pulse generator) designed to promote airway clearance and improve bronchial drainage by mechanically compressing and releasing the chest wall at high frequency.

IPV (Intrapulmonary Percussive Ventilation) — a device that delivers percussive breaths or mini-bursts of gas to the lungs (high-frequency intrapulmonary percussion) to mobilize secretions and assist airway clearance.

OLE (Oscillation and Lung Expansion) — combination therapy using continuous positive expiratory pressure (CPEP), continuous high frequency oscillation (CHFO), and nebulized medications to provide oscillation and lung expansion for postoperative or other high-risk respiratory management.

Revision History

2026-01-01revisedLatest

Template update only; no clinical policy statement changes noted.